DE2713389C2 - - Google Patents

Info

Publication number
DE2713389C2
DE2713389C2 DE2713389A DE2713389A DE2713389C2 DE 2713389 C2 DE2713389 C2 DE 2713389C2 DE 2713389 A DE2713389 A DE 2713389A DE 2713389 A DE2713389 A DE 2713389A DE 2713389 C2 DE2713389 C2 DE 2713389C2
Authority
DE
Germany
Prior art keywords
methyl
butyl
compounds
dimethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE2713389A
Other languages
German (de)
English (en)
Other versions
DE2713389A1 (de
Inventor
Julius Morris Plains N.J. Us Diamond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/672,437 external-priority patent/US4089959A/en
Priority claimed from US05/672,388 external-priority patent/US4120947A/en
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Publication of DE2713389A1 publication Critical patent/DE2713389A1/de
Application granted granted Critical
Publication of DE2713389C2 publication Critical patent/DE2713389C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19772713389 1976-03-31 1977-03-23 Neuartige xanthinverbindungen und dieselben enthaltende pharmazeutische zubereitung Granted DE2713389A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/672,437 US4089959A (en) 1976-03-31 1976-03-31 Long-acting xanthine bronchodilators and antiallergy agents
US05/672,388 US4120947A (en) 1976-03-31 1976-03-31 Xanthine compounds and method of treating bronchospastic and allergic diseases

Publications (2)

Publication Number Publication Date
DE2713389A1 DE2713389A1 (de) 1977-10-13
DE2713389C2 true DE2713389C2 (zh) 1992-03-19

Family

ID=27100746

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19772713389 Granted DE2713389A1 (de) 1976-03-31 1977-03-23 Neuartige xanthinverbindungen und dieselben enthaltende pharmazeutische zubereitung

Country Status (5)

Country Link
JP (1) JPS52122396A (zh)
CA (1) CA1077932A (zh)
DE (1) DE2713389A1 (zh)
FR (1) FR2346353A1 (zh)
GB (1) GB1561005A (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416810C (sv) * 1977-10-14 1982-05-11 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
FR2611716A1 (fr) * 1987-03-06 1988-09-09 Uriach Cia Sa J Derives de diisobutylxanthine substituee en position 7 utiles comme bronchodilatateurs, procede pour leur preparation et composition pharmaceutique les contenant
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
DE69531506T2 (de) 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
ATE247655T1 (de) 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2729643A (en) * 1956-01-03 J-disubstmjied and i

Also Published As

Publication number Publication date
JPS52122396A (en) 1977-10-14
DE2713389A1 (de) 1977-10-13
CA1077932A (en) 1980-05-20
GB1561005A (en) 1980-02-13
JPS5720313B2 (zh) 1982-04-27
FR2346353B1 (zh) 1980-03-07
FR2346353A1 (fr) 1977-10-28

Similar Documents

Publication Publication Date Title
DE2713389C2 (zh)
DD203052A5 (de) Verfahren zur herstellung von 9-(1,3-dihydroxy-2-propoxy-methyl)-guanin, dessen salzen und bestimmten benzylderivaten desselben
DD202001A5 (de) Verfahren zur herstellung von aminoaethanolen
DD146708A5 (de) Verfahren zur herstellung von 3-alkylxanthinen
EP0063381A1 (de) Neue Pyrazolo(3,4-d)pyrimidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
DD139855A5 (de) Verfahren zur herstellung von xanthinderivaten
DE2165962A1 (de) 4-Hydroxy-6-arylpyrimidine. Ausscheidung aus: 2149249
DE2305092C2 (zh)
DE1946315C2 (de) 4,5-Dihydro-5-oxo-s-triazolo-[1,5-a]-pyrimidin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE3717080C2 (de) 1-(Hydroxystyryl)-5H-2,3-benzodiazepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
AT391864B (de) Verfahren zur herstellung von neuen 5-pyrimidincarboxamiden und deren additionssalzen
DE2716402A1 (de) 7-(2,3-dihydroxypropyl)-1,3-di-n- propylxanthin, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel
DE3320394A1 (de) Optisch aktive n-arylierte oxazolidinon-(2)-derivate, deren verwendung als spezifische und reversible inhibitoren von monoaminooxydase des b-typs sowie verfahren zu deren herstellung
EP0132811A1 (de) In 1-Stellung substituierte 4-Hydroxymethyl-pyrrolidinone, Verfahren zu ihrer Herstellung, pharmazeutische Zusammensetzungen und Zwischenprodukte
EP0018360B1 (de) N-(5-Methoxybentofuran-2-ylcarbonyl)-N'-benzylpiperazin und Verfahren zu dessen Herstellung
DE3439450A1 (de) 1,2,4-triazolo-carbamate und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
EP0224159B1 (de) Neue basisch substituierte Pyridinverbindungen, Verfahren zu ihrer Herstellung, die sie enthaltenden Arzneimittel und ihre Verwendung
DE2900288A1 (de) Aminoderivate von pyrazol eckige klammer auf 1,5-a eckige klammer zu s-triazin, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE3419223C2 (de) Substituierte Acylpiperazinochinazoline, ein Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE2632118B2 (de) Apovincaminolester und Verfahren zu deren Herstellung und Arzneimittel
DE2651789A1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2264374B2 (de) 4-Hydroxy-5-phenoxy-pyrilnidine, Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Präparat
DE3337925C2 (de) N-(6-Aminopurinyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxid, Verfahren zu dessen Herstellung und seine Verwendung
DE2755707A1 (de) Verfahren zur herstellung von neuen piperazinderivaten
AT390062B (de) Verfahren zur herstellung von neuen trifluormethyl substituierten tetracyclischen chinazolinonen und ihrer saeureadditionssalze

Legal Events

Date Code Title Description
OD Request for examination
OGA New person/name/address of the applicant
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee